The impact of non-compliance on the cost
β
Dyfrig A. Hughes; Adrian Bagust; Alan Haycox; Tom Walley
π
Article
π
2001
π
John Wiley and Sons
π
English
β 122 KB
π 1 views
## Abstract Nonβcompliance with drug therapies not only limits their effectiveness, but in some instances, is associated with grave clinical sequelae and substantial economic burden. It is important, therefore, to consider nonβcompliance in economic evaluations. A review of pharmacoeconomic evaluat